TY - JOUR
T1 - Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis
AU - Selenica, Maj Linda B.
AU - Davtyan, Hayk
AU - Housley, Steven B.
AU - Blair, Laura J.
AU - Gillies, Anne
AU - Nordhues, Bryce A.
AU - Zhang, Bo
AU - Liu, Joseph
AU - Gestwicki, Jason E.
AU - Lee, Daniel C.
AU - Gordon, Marcia N.
AU - Morgan, Dave
AU - Dickey, Chad A.
N1 - Publisher Copyright:
© 2014 Selenica et al.; licensee BioMed Central Ltd.
PY - 2014/9/3
Y1 - 2014/9/3
N2 - Background: Abnormal tau hyperphosphorylation and its accumulation into intra-neuronal neurofibrillary tangles are linked to neurodegeneration in Alzheimer's disease and similar tauopathies. One strategy to reduce accumulation is through immunization, but the most immunogenic tau epitopes have so far remained unknown. To fill this gap, we immunized mice with recombinant tau to build a map of the most immunogenic tau epitopes. Methods: Non-transgenic and rTg4510 tau transgenic mice aged 5 months were immunized with either human wild-type tau (Wt, 4R0N) or P301L tau (4R0N). Each protein was formulated in Quil A adjuvant. Sera and splenocytes of vaccinated mice were collected to assess the humoral and cellular immune responses to tau. We employed a peptide array assay to identify the most effective epitopes. Brain histology was utilized to measure the effects of vaccination on tau pathology and inflammation. Results: Humoral immune responses following immunization demonstrated robust antibody titers (up to 1:80,000 endpoint titers) to each tau species in both mice models. The number of IFN-γ producing T cells and their proliferation were also increased in splenocytes from immunized mice, indicating an increased cellular immune response, and tau levels and neuroinflammation were both reduced. We identified five immunogenic motifs within either the N-terminal (9-15 and 21-27 amino acids), proline rich (168-174 and 220-228 amino acids), or the C-terminal regions (427-438 amino acids) of the wild-type and P301L tau protein sequence. Conclusions: Our study identifies five previously unknown immunogenic motifs of wild-type and mutated (P301L) tau protein. Immunization with both proteins resulted in reduced tau pathology and neuroinflammation in a tau transgenic model, supporting the efficacy of tau immunotherapy in tauopathy.
AB - Background: Abnormal tau hyperphosphorylation and its accumulation into intra-neuronal neurofibrillary tangles are linked to neurodegeneration in Alzheimer's disease and similar tauopathies. One strategy to reduce accumulation is through immunization, but the most immunogenic tau epitopes have so far remained unknown. To fill this gap, we immunized mice with recombinant tau to build a map of the most immunogenic tau epitopes. Methods: Non-transgenic and rTg4510 tau transgenic mice aged 5 months were immunized with either human wild-type tau (Wt, 4R0N) or P301L tau (4R0N). Each protein was formulated in Quil A adjuvant. Sera and splenocytes of vaccinated mice were collected to assess the humoral and cellular immune responses to tau. We employed a peptide array assay to identify the most effective epitopes. Brain histology was utilized to measure the effects of vaccination on tau pathology and inflammation. Results: Humoral immune responses following immunization demonstrated robust antibody titers (up to 1:80,000 endpoint titers) to each tau species in both mice models. The number of IFN-γ producing T cells and their proliferation were also increased in splenocytes from immunized mice, indicating an increased cellular immune response, and tau levels and neuroinflammation were both reduced. We identified five immunogenic motifs within either the N-terminal (9-15 and 21-27 amino acids), proline rich (168-174 and 220-228 amino acids), or the C-terminal regions (427-438 amino acids) of the wild-type and P301L tau protein sequence. Conclusions: Our study identifies five previously unknown immunogenic motifs of wild-type and mutated (P301L) tau protein. Immunization with both proteins resulted in reduced tau pathology and neuroinflammation in a tau transgenic model, supporting the efficacy of tau immunotherapy in tauopathy.
KW - Active immunization
KW - Immunogenicity
KW - Neuroinflammation
KW - Peripheral response
KW - Tau
UR - http://www.scopus.com/inward/record.url?scp=84908130851&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908130851&partnerID=8YFLogxK
U2 - 10.1186/s12974-014-0152-0
DO - 10.1186/s12974-014-0152-0
M3 - Article
C2 - 25183004
AN - SCOPUS:84908130851
SN - 1742-2094
VL - 11
JO - Journal of Neuroinflammation
JF - Journal of Neuroinflammation
IS - 1
M1 - 152
ER -